Download PDF

下载PDF

Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts Investigator-Sponsored Trial (IST) expands the development of NKX019 to neuromuscular autoimmune disease myasthenia gravis Patient dosing initiated and enrollment open in Ntrust-1 and IST of NKX019 in systemic lupus erythematosus Clinical data from Ntrust-1 and Ntrust-2 planned for 2025 SOUTH SAN FRANCISCO, Calif., Dec.

Ntrust-2开放在三个平行队列中招募系统性硬化症，肌炎和ANCA相关性血管炎患者研究者赞助的试验（IST）将NKX019的发展扩展到神经肌肉自身免疫性疾病重症肌无力患者给药，并在Ntrust-1和IST中开放NKX019在系统性红斑狼疮中的注册Ntrust-1和Ntrust-2的临床数据计划于2025年12月在加利福尼亚州南旧金山进行。

05, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the opening of Ntrust-2 to enrollment and the IND clearance for an investigator-sponsored trial (IST) that will evaluate NKX019, Nkarta’s allogeneic, CD19-directed chimeric antigen receptor (CAR) NK-cell therapy, in patients with myasthenia gravis (MG).

2024年5月5日（环球通讯社）--开发工程自然杀伤（NK）细胞疗法的生物制药公司Nkarta，Inc.（纳斯达克代码：NKTX）今天宣布Ntrust-2开放注册，并获得IND批准，用于研究者赞助的试验（IST），该试验将评估NKX019，即Nkarta的同种异体CD19定向嵌合抗原受体（CAR）NK细胞疗法，用于重症肌无力（MG）患者。

Ntrust-2, a multi-center clinical trial, will evaluate NKX019 across three parallel cohorts, including patients with systemic sclerosis (SSc, scleroderma), idiopathic inflammatory myopathy (IIM, myositis) and ANCA-associated vasculitis (AAV). The IST will be led by researchers at the University of California, Irvine and the University of Kansas Medical Center.

Ntrust-2是一项多中心临床试验，将在三个平行队列中评估NKX019，包括系统性硬化症（SSc，硬皮病），特发性炎性肌病（IIM，肌炎）和ANCA相关性血管炎（AAV）患者。IST将由加利福尼亚大学欧文分校和堪萨斯大学医学中心的研究人员领导。

NKX019 is an allogeneic, off-the-shelf, chimeric antigen receptor (CAR) NK-cell therapy candidate engineered to deplete CD19-positive cells in B-cell mediated disease. The approach leverages the potential advantages of NK cell therapy, including rapid B-cell killing without the need for cell expansion, a lower risk of toxicities associated with rapid cell expansion, fludarabine-free lymphodepletion to reduce toxicity, and the added utility of on-demand dosing, including the opportunity for repeated dosing as needed.

NKX019是一种同种异体，现成的嵌合抗原受体（CAR）NK细胞治疗候选物，旨在消耗B细胞介导的疾病中的CD19阳性细胞。该方法利用了NK细胞疗法的潜在优势，包括无需细胞扩增即可快速杀死B细胞，与快速细胞扩增相关的毒性风险较低，无氟达拉滨的淋巴细胞清除以降低毒性，以及按需给药的附加效用，包括根据需要重复给药的机会。

“The expansion to these four autoimmune indicati.

“扩展到这四种自身免疫指标。